Doxorubicin

Doxorubicin

Doxorubicin is an antibiotic with a broad antineoplastic activity that is obtained from a Streptomyces peucetius bacterium and is injected in the form of hydrochloride. This drug is used to treat different cancers such as kidney, ovarian, liver, ovarian, and others. This drug works by with interfering the DNA of cancerous cells and preventing them to grow and divide. The rising prevalence of cancerous diseases is the primary factor for the market growth of the doxorubicin market. For instance, according to the World Health Organisation (WHO), cancer is the primary cause of death worldwide accounting for 10 million deaths in 2020.

Doxorubicin Market is expected to grow at a strong CAGR of 7% during the forecast period owing the technological advancements and frequent product launches. For instance, In December 2019, Capstone announced the FDA Approval and EU Authorization of Doxorubicin Hydrochloride Liposome Injection.

• Based on drug formulation, the market is segmented into lyophilized powder and doxorubicin injection. The lyophilized powder segment acquired a major share in 2021. The Lyophilized powders are commonly used because they have a longer shelf life and are easy to transport and stored. Further, the lyophilized powder is more stable which is also an important reason for the significant market share of the segment in the doxorubicin market.
• Based on the application, the market is segmented into bladder cancer, kaposi sarcoma, leukemia, lymphoma, breast cancer, and others. The leukemia segment is expected to grow with a higher CAGR in the doxorubicin market during the forecast period. The prevalence of leukemia is high and the cases of the disease are growing at a rapid pace is an important factor responsible for the growth of the segment. For instance, as per the American Cancer Society, an estimated 59,610 new cases of leukemia and 23,710 deaths from leukemia will report in 2023.
• Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment acquired a major share in 2021. This is mainly due to the hospital pharmacies having the necessary licenses for the distribution of these and patients also prefer hospital pharmacies due to their presence inside the hospital makes the drug availability easy.
• For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North American region held dominant share in doxorubicin market in 2021. This is mainly due to the increasing prevalence of the geriatric population and the increased prevalence of cancer in them. Further, the increasing product launches and expansion of market players in the North American market are also responsible for the market growth of Doxorubicin in North America. For instance, as per the Population Reference Bureau, the number of Americans 65 and older is expected to nearly double, from 52 million in 2018 to 95 million in 2060, and the share of those 65 and older in the total population will increase from 16% to 23%.
• Some of the major players operating in the market include Intas Pharmaceuticals Ltd.; Cipla Inc.; Dr. Reddy’s Laboratories Ltd.; Cadila Pharmaceuticals; Meiji Holdings Co., Ltd.; Johnson & Johnson Private Limited.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; and Baxter.